Viking Therapeutics (VKTX) Interest Expenses (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Interest Expenses data on file, last reported at $101.0 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 52.13% year-over-year to $101.0 million; the trailing twelve-month figure through Mar 2026 stood at $101.0 million (up 52.13% YoY), and the FY2025 full-year result was $114.0 million, down 30.51% from the prior year.
• Interest Expenses retreated to $101.0 million in Q1 2026, from $114.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $60.3 billion in Q1 2023 to a low of $1.8 million in Q3 2022.
• A 5-year average of $7.9 billion and a median of $101.0 million in 2026 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 3368241.71% in 2023 and slumped 99.55% in 2024, its largest moves.
• Tracing VKTX's Interest Expenses over 5 years: stood at $20.5 million in 2022, then jumped by 203.24% to $62.2 million in 2023, then soared by 127.13% to $141.3 million in 2024, then declined by 19.32% to $114.0 million in 2025, then dropped by 11.4% to $101.0 million in 2026.
• Business Quant data shows VKTX's Interest Expenses at $101.0 million in Q1 2026, $114.0 million in Q4 2025, and $75.0 million in Q3 2025.